Inhibitor of Interleukin-1 Receptor-associated Kinases 1/4, Can Increase the Sensitivity of Breast Cancer Cells to Methotrexate

Overview

Journal Int J Mol Cell Med

Specialty Genetics

Date 2020 Jun 4

PMID 32489949

Citations 2

Authors

Samaneh Rahemi

Seyed Noureddin Nematollahi-Mahani

Athena Rajaie

Hossein Fallah

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common type of cancer among women. Chemotherapy is one of the main methods of breast cancer treatment, but this method is increasingly affected due to drug resistance. One of the newly discovered factors associated with drug resistance in cancer cells is interleukin receptor-associated kinase 1 (IRAK1). The aim of this study was to investigate the relationship between IRAK1 inhibition and sensitivity to methotrexate (MTX). Effects of various concentrations of MTX and constant concentration (1μg/ml) of IRAK1/4 inhibitor was examined on MCF-7, BT-20, BT-549, MB-468 cell lines. Cell viability was examined by water soluble tetrazole -1, and cell apoptosis by flow cytometry. The expression of and genes was also assessed by real-time PCR method. IRAK1 inhibitor decreased IC in all examined cell lines, but the most prominent effect was observed in MB-468. 72 h incubation of cell lines with IRAK inhibitor and MTX, significantly increased the annexin-V and annexin-V/7AAD positive cells, suggesting an apoptotic effect of IRAK on all examined breast cancer cell lines. RT-qPCR test results showed that the IRAK inhibitor had no effect on the expression of at any time. Our results showed that IRAK inhibitor can increase the chemosensitivity of breast cancer cell lines without effect on mRNA expression. IRAK inhibitor in combination with MTX can induce apoptosis in breast cancer cell lines.

Citing Articles

Enzymatic TET-1 inhibition highlights different epigenetic behaviours of IL-1β and TNFα in tumour progression of OS cell lines.

Bellavia D, Caruccio S, Caradonna F, Costa V, Urzi O, Raimondi L Clin Epigenetics. 2024; 16(1):136.

PMID: 39358792 PMC: 11448002. DOI: 10.1186/s13148-024-01745-4.

Interleukin-1 receptor associated kinase 1 (IRAK1) is epigenetically activated in luminal epithelial cells in prostate cancer.

Schagdarsurengin U, Breiding V, Loose M, Wagenlehner F, Dansranjav T Front Oncol. 2022; 12:991368.

PMID: 36226067 PMC: 9549294. DOI: 10.3389/fonc.2022.991368.

References

Bontempo A, Ugalde-Villanueva B, Delgado-Gonzalez E, Luis Rodriguez A, Aceves C . Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin. Oncol Rep. 2017; 38(5):2867-2876. DOI: 10.3892/or.2017.5934. View

Robey R, Polgar O, Deeken J, To K, Bates S . ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007; 26(1):39-57. DOI: 10.1007/s10555-007-9042-6. View

Boukerche H, Su Z, Kang D, Fisher P . Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. Gene. 2004; 343(1):191-201. DOI: 10.1016/j.gene.2004.09.002. View

Cheng B, Lau E, Leung H, Leung C, Ho N, Gurung S . IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. Cancer Res. 2018; 78(9):2332-2342. DOI: 10.1158/0008-5472.CAN-17-2445. View

Van Waes C . Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res. 2007; 13(4):1076-82. DOI: 10.1158/1078-0432.CCR-06-2221. View

Maeda S, Omata M . Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008; 99(5):836-42. PMC: 11159293. DOI: 10.1111/j.1349-7006.2008.00763.x. View

Nakanishi T, Ross D . Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2011; 31(2):73-99. PMC: 3777471. DOI: 10.5732/cjc.011.10320. View

Rajendra R, Gounder M, Saleem A, Schellens J, Ross D, Bates S . Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res. 2003; 63(12):3228-33. View

Snyder M, Huang J, Huang X, Zhang J . A signal transducer and activator of transcription 3·Nuclear Factor κB (Stat3·NFκB) complex is necessary for the expression of fascin in metastatic breast cancer cells in response to interleukin (IL)-6 and tumor necrosis factor (TNF)-α. J Biol Chem. 2014; 289(43):30082-9. PMC: 4208015. DOI: 10.1074/jbc.M114.591719. View

10.

Gao F, Liu J, Dong W, Wang W, Wang Y, Cai D . Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells. Oncol Rep. 2013; 31(2):926-32. DOI: 10.3892/or.2013.2930. View

11.

Kovalev A, Tsvetaeva D, Grudinskaja T . Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 2014; 35(4):287-90. View

12.

Cherigo L, Lopez D, Martinez-Luis S . Marine natural products as breast cancer resistance protein inhibitors. Mar Drugs. 2015; 13(4):2010-29. PMC: 4413197. DOI: 10.3390/md13042010. View

13.

Ng Z, Ong M, Jegadeesan T, Deng S, Yap C . Breast Cancer: Exploring the Facts and Holistic Needs during and beyond Treatment. Healthcare (Basel). 2017; 5(2). PMC: 5492029. DOI: 10.3390/healthcare5020026. View

14.

Zhang D, Li L, Jiang H, Knolhoff B, Lockhart A, Wang-Gillam A . Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2016; 23(7):1748-1759. PMC: 5378683. DOI: 10.1158/1078-0432.CCR-16-1121. View

15.

deGraffenried L, Chandrasekar B, Friedrichs W, Donzis E, Silva J, Hidalgo M . NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol. 2004; 15(6):885-90. DOI: 10.1093/annonc/mdh232. View

16.

Pasquier J, Magal P, Boulange-Lecomte C, Webb G, Le Foll F . Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model. Biol Direct. 2011; 6:5. PMC: 3038988. DOI: 10.1186/1745-6150-6-5. View

17.

Han Z, Shi L . Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun. 2017; 495(1):947-953. DOI: 10.1016/j.bbrc.2017.11.121. View

18.

Sodani K, Tiwari A, Singh S, Patel A, Xiao Z, Chen J . GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol. 2012; 83(12):1613-22. PMC: 3360928. DOI: 10.1016/j.bcp.2012.02.028. View

19.

Wee Z, Yatim S, Kohlbauer V, Feng M, Goh J, Bao Y . IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun. 2015; 6:8746. PMC: 4640083. DOI: 10.1038/ncomms9746. View

20.

Muzio M, Mantovani A . Toll-like receptors (TLRs) signalling and expression pattern. J Endotoxin Res. 2001; 7(4):297-300. View